Catalog |
name |
Description |
price |
R-XASYS-00727 |
Avatrombopag,cas:570406-98-3 |
Avatrombopag (C29H34Cl2N6O3S2,649.7) is an orally active, nonpeptide thrombopoietin (TPO) receptor agonist (EC50=3.3 nM). Avatrombopag mimics the biological activities of TPO. Avatrombopag increases platelet production by activating the intracellular signaling system, and promotes production of platelets and megakaryocytes from hemopoietic precursor cells. Avatrombopag is a substrate of cytochrome P450 (CYP) 2C9 and CYP3A. |
price> |
R-XASYS-00728 |
AVE 0991 sodium salt,cas:306288-04-0 |
AVE 0991 sodium salt(C29H31N4NaO5S2,602.70) is a nonpeptide and orally active Ang-(1-7) receptor Mas agonist. AVE 0991 competes for high-affinity binding of [125I]-Ang-(1-7) to bovine aortic endothelial cell membranes with IC50 of 21 nM. |
price> |
R-XASYS-00729 |
AVE-3085,cas:450348-85-3 |
AVE3085(C17H13F2NO3,317.29) is a potent endothelial nitric oxide synthase enhancer, used for cardiovascular disease treatment. |
price> |
R-XASYS-00730 |
AVN-492,cas:1220646-23-0 |
AVN-492(C17H21N5O2S,359.4) is an antagonist of the serotonin (5-HT) receptor subtype 5-HT6 (Ki = 0.09 nM). It selectively inhibits the 5-HT6 receptor over the 5-HT2B receptor (IC50s = 0.19 and 268 nM, respectively, in a radioligand binding assay). AVN-492 inhibits increases in cAMP levels induced by 5-HT in HEK293 cells expressing the 5-HT6 receptor (IC50 = 1.5 nM). |
price> |
R-XASYS-00731 |
AVX 13616,cas:900814-48-4 |
AVX 13616(C50H73Cl2N7O7,955.06) shows the potent in vivo antibacterial activity of Avexas lead antibacterial candidate; particularly against drug-resistant Staphylococcus pathogens. |
price> |
R-XASYS-00732 |
AX-024 hydrochloride,cas:1704801-24-0 |
AX-024 hydrochloride(C21H23ClFNO2,375.86) is an orally available, first-in-class inhibitor of the TCR-Nck interaction that selectively inhibits TCR-triggered T cell activation with an IC50 ~1 nM. AX-024 hydrochloride modulates cell signaling by targeting SH3 domains. AX-024 hydrochloride has low-acute toxicity and high potency and selectivity, and strongly inhibit the production of IL-6, TNF-α, IFN-γ, IL-10 and IL-17A. |
price> |
R-XASYS-00733 |
AX-15836,cas:2035509-96-5 |
AX-15836(C32H40N8O5S,648.78) is a potent and selective ERK5 inhibitor with an IC50 of 8 nM. |
price> |
R-XASYS-00734 |
AZ PFKFB3 26,cas:1704740-52-2 |
AZ PFKFB3 26(C24H26N4O2,402.49) is a potent and selective inhibitor of the metabolic kinase PFKFB3 with an IC50 of 23 nM. AZ PFKFB3 26 inhibits PFKFB1 and PFKFB2 with IC50s of 2.06 and 0.384 μM, respectively. |
price> |
R-XASYS-00735 |
AZ-1355,cas:75451-07-9 |
AZ-1355(C17H17NO4,299.32) is an effctive lipid-lowering compound, which also inhibits platelet aggregation in vivo and elevates the prostaglandin I2/thromboxane A2 ratio in vitro. |
price> |
R-XASYS-00736 |
AZ12672857,cas:945396-55-4 |
AZ12672857(C26H30N8O2,486.57) is an orally active inhibitor of EphB4 (IC50=1.3 nM) and Src kinases. AZ12672857 shows good inhibition of proliferation of c-Src transfected 3T3 cells (IC50=2 nM) as well as autophosphorylation of EphB4 in transfected CHO-K1 cells (IC50=9 nM). |
price> |